Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Filings indexed 1,663 across all filing types
Latest filing 2025-11-17 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2025-11-17 English
AVR Presents Data from 100 DurAVR THV Patients 3 pages 205.5KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical trial data and outcomes for Anteris Technologies' DurAVR Transcatheter Heart Valve (THV). It presents 30-day clinical results from a study cohort and references ongoing and future clinical trials. The text includes detailed clinical outcome highlights, references to scientific publications, and forward-looking statements. There is no indication that this is a full financial report, audit report, earnings release, or regulatory filing. It is not a presentation or transcript of a call, nor is it a governance or management change announcement. The document is a corporate announcement focused on clinical data and product development progress, which fits best under the category of a general Regulatory Filing (RNS) as it does not fit any other specific category and is a regulatory announcement of clinical data results.
2025-11-16 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-13 English
8-K
Regulatory Filings
2025-11-12 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.